12:10 AM EST, 11/04/2025 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows:

We lift our 12-month target price by $4 to $27, valuing IVZ shares at 9.3x our newly initiated 2027 EPS estimate of $2.90 and at 10.8x our 2026 EPS estimate of $2.50 (raised by $0.30), vs. its three-year average forward multiple of 10x and a disparate peer average of 17x. We lift our 2025 EPS estimate by $0.13 to $1.95. Q3 adjusted EPS of $0.61 vs. $0.44 topped our Q3 $0.48 EPS estimate, the $0.44 consensus EPS forecast, on 8.2% GAAP revenue growth (above our forecast of a 3% to 6% rise). The results reflected Q3 fund inflows, which totaled $26.1B (vs. inflows of $12.7B a year ago and $15.2B of inflows in Q2). We raise our 2025 revenue forecast to a rise of 5% to 9% (from 3% to 6%). We believe these results, coupled with IVZ plan to convert its core QQQ ETF to an open-ended fund structure (and potentially recapture up to $600M in gross fees), subject to a December 5 shareholder vote, provide the shares with a catalyst to close some of its valuation gap to peers. The shares currently yield 3.5%.